Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin - Wikidata - wikimedia - TriplyDB

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

http://www.wikidata.org/entity/Q34233163

about

Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study Cirrhosis and its complications: evidence based treatment.Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures.Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort Treatment of chronic delta hepatitis: a nine-year retrospective analysis.Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.Treatment of hepatitis C virus infection in the future.Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure.Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: results from the DANVIR cohort study.

P2860

Q26777659-47100F28-774D-46F2-9AC4-DD319349E386 Q28075646-CC60FAA3-D930-4EB9-9BA2-2AD6CE5DEA26 Q28479129-31BE92EA-DBB1-4DCE-9E4A-05C2B70462ED Q33594931-D6F1E8C0-A766-42A4-8CBC-81F1036A6F4F Q33731308-FED56B5E-8B57-49D8-891E-AC64021B49E4 Q34172595-67F8C3E3-5EBF-429D-A189-F897A677E101 Q34411907-E8282EEB-6265-46C7-AA66-2C9BAC138D49 Q34420891-BDF98087-1973-49EC-9B6A-D5B87FCF72C4 Q34424151-0FAA1E71-9DFC-4655-B80A-A2911FCB6CAB Q34497272-63D84491-3913-4BDF-B0FA-4849D66E51FE Q34987336-AD444F46-86B0-4763-AD1F-6BB08D8D85AF Q35164782-22367EB3-83F4-409B-8ABC-482A6E9B715C Q35603743-6E66255C-15EF-49E1-990F-A6D80A629BA5 Q35833170-9B76B690-EC4A-4E04-89B7-0341BF095237 Q35933802-AF1DB4CD-D741-4573-831D-10D3DD39F7C5 Q36145716-F7051914-A0DA-4C1C-8287-35479C09660D Q36334385-213739CF-92ED-403F-93E6-4BF7D2B6B649 Q36935025-E73795CA-B4C2-4BAC-B898-26BEF1DE7824 Q37534731-F1C20920-93EA-47EA-A9B3-8E98655FE444 Q37650394-D3D07803-E2D5-4E7E-90C0-E9E2B99DDB7A Q38233860-2360F39F-2DB8-4173-8A84-1F2ACE4C8A3D Q38235178-55F6C270-A9CD-4BD3-974C-58589A89BE1D Q38237281-6577092C-A31B-4974-9ADE-2B974A1CBDC4 Q38522791-983A6C4A-6E61-4247-8520-C4FCCC08C6AE Q39436509-E5D2680F-137C-473E-B25C-B0A8488EDED3 Q39564809-8033F5CB-1D57-45DA-85C1-963F98673C26 Q40201286-9C131F0C-107C-43AB-8C31-9F6B42B06C13 Q42255898-F0E7682F-F991-46A2-B333-417E604D002B Q42986494-6B63BD5D-ED76-494D-A0D2-DDFEEB4C853E Q43409999-D79EE13F-C030-4FB5-8773-45BD4505AD66

P2860

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

http://www.wikidata.org/entity/Q34233163

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Effect of sustained virologica ...... interferon alpha and ribavirin

@ast

Effect of sustained virologica ...... interferon alpha and ribavirin

@en

Effect of sustained virologica ...... interferon alpha and ribavirin

@nl

type

label

Effect of sustained virologica ...... interferon alpha and ribavirin

@ast

Effect of sustained virologica ...... interferon alpha and ribavirin

@en

Effect of sustained virologica ...... interferon alpha and ribavirin

@nl

prefLabel

Effect of sustained virologica ...... interferon alpha and ribavirin

@ast

Effect of sustained virologica ...... interferon alpha and ribavirin

@en

Effect of sustained virologica ...... interferon alpha and ribavirin

@nl

P1433

Q34233163-B43899B4-E35C-4D0B-B242-B284E792F44B

P1476

Q34233163-A4FC68A6-BA4C-42B7-9819-152DFC92DE13

P2093

Q34233163-39B9479B-DD36-4592-994D-A322FC3F5E26

Q34233163-46DBCE31-8585-4F15-A4F4-4DB8D08D39F3

Q34233163-4EB5AEFD-D27C-435B-9D88-FA6AB466220F

Q34233163-97B76129-F9DC-428D-8DA3-1F2BCD0FE54A

Q34233163-A5CCA453-4E39-46E9-8949-BBAB9B1C8E3E

Q34233163-E358BAEF-4705-489D-86CF-A0E044AE72C1

Q34233163-E42AC60D-74CF-48EB-956C-9EF4CCEBEA8F

P2860

Q34233163-0812F18B-6623-4662-938C-F2263D31B771

Q34233163-0BC25DE6-DCC9-4635-A8B2-8EF27AC2B8D7

Q34233163-1EA20CA0-F93A-40C4-8085-E689895149EE

Q34233163-2AEE1774-2ADB-4181-AE11-29C93C135D56

Q34233163-64657A58-2920-45C9-81FC-E4FE05C28369

Q34233163-67D48D5E-F731-41BD-B5D9-AB9A757C0FD1

Q34233163-71134A31-C03E-4AF7-8A31-2688E2EB1303

Q34233163-7EA1A4EA-5A90-4E20-9A3F-8278C740308F

Q34233163-85ABA962-1189-440B-8297-F2CC43D493F1

Q34233163-864785B6-1B6B-4C77-AE47-A42D678CF1EC

P304

Q34233163-EBF4E680-06EE-4C5D-87E5-D13CA10FB7EC

P31

Q34233163-470AABAC-3436-4E4D-8446-BC7A3A6D0CF9

P356

Q34233163-62D8E050-AF85-404A-A290-DCBD5485CE68

P407

Q34233163-B15479F3-B922-48FC-B5A2-6E78FB3D0CE5

P433

Q34233163-492FFB33-1C17-42B0-9DF1-1068AF547086

P478

Q34233163-D4D31B84-561D-410F-9C14-8AB523F6DCCF

P50

Q34233163-42B667B5-6C86-4A7E-9EE5-FC61E0C300B1

P577

Q34233163-C1BC8C72-72EF-46CB-9158-5227BC2F6C15

P698

Q34233163-A079B89A-5792-48FC-8167-13E1BE03711F

P921

Q34233163-18948379-52FC-426A-9DEF-59912E1920C8

Q34233163-CDA1E2C2-B5DB-47D4-B0AB-9BA97DF87A43

P932

Q34233163-B21D372A-E106-4EEF-99CF-9823F0EC330D

P356

WJG.V13.I42.5648

P1433

World Journal of Gastroenterology

P1476

Effect of sustained virologica ...... interferon alpha and ribavirin

@en

P2093

Helene Fontaine

http://www.w3.org/2001/XMLSchema#string

Jacques Paries

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Trinchet

http://www.w3.org/2001/XMLSchema#string

Michel Beaugrand

http://www.w3.org/2001/XMLSchema#string

Nathalie Ganne-Carrie

http://www.w3.org/2001/XMLSchema#string

Roland El Braks

http://www.w3.org/2001/XMLSchema#string

Veronique Grando-Lemaire

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

Prevention of hepatitis C virus-related hepatocellular carcinoma.

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.

P304

5648-5653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V13.I42.5648

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17948941

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

P932

4172746

http://www.w3.org/2001/XMLSchema#string